International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments – introduction
Authors:
- 15 July 2010
- journal article
- editorial
- Published by Wiley in European Journal of Neurology
- Vol. 17 (s2) , 1-8
Abstract
Botulinum neurotoxin (BoNT) is most commonly used to reduce focal over‐activity in skeletal muscle, although newer indications such as management of drooling, pain and tremor are emerging. Treatment of spasticity incorporating BoNT is usually part of an integrated multidisciplinary rehabilitation programme. Prior to initiating this therapy, specific functional limitations, goals and expected outcomes of treatment should be discussed with the patient/carers. Muscle selection and the order/priority of treatment should be agreed. Treatment goals may involve increasing active or passive function or the avoidance of secondary complications or impairment progression. This paper describes the basic science mechanisms of the action of BoNT and subsequent nerve recovery and introduces a supplement comprising the best available evidence and expert opinion from international panels on questions of assessment, indications, BoNT regimen, adjunctive therapy, expected outcomes and recommended monitoring. Speciality areas reviewed include Paediatric Lower Limb Hypertonicity, Paediatric Upper Limb Hypertonicity, Adult Lower Limb Hypertonicity, Adult Upper Limb Hypertonicity, Cervical Dystonia, Drooling and Pain and Niche Indications. There is good quality scientific evidence to support the efficacy of BoNT to reduce muscle over‐activity in the limbs secondary to central nervous system disorders in adults and children, to address primary or secondary cervical dystonia, to reduce saliva flow and to treat some pain syndromes. There is emergent evidence for the efficacy of BoNT to reduce focal tremor, to treat other types of pain including neuropathic pain and also to improve function following treatment of focal muscle over‐activity.Keywords
This publication has 32 references indexed in Scilit:
- Botulinum toxin for the management of adult patients with upper motor neuron syndromeToxicon, 2009
- Botulinum neurotoxins for post‐stroke spasticity in adults: A systematic reviewMovement Disorders, 2009
- Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidenceJournal of Neural Transmission, 2009
- European consensus table on the use of botulinum toxin type A in adult spasticityJournal of Rehabilitation Medicine, 2009
- Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): [RETIRED]Neurology, 2008
- Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review) [RETIRED]Neurology, 2008
- Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review) [RETIRED]Neurology, 2008
- Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticityJournal of Neural Transmission, 2008
- Effects of botulinum toxin type A on upper limb function in children with cerebral palsy: a systematic reviewClinical Rehabilitation, 2006
- Safety of botulinum toxin type A: a systematic review and meta-analysisCurrent Medical Research and Opinion, 2004